News

Filter

1 to 9 of 415 results

Janssen disappointed at SMC decision on Zytiga

09-02-2015

Janssen, a UK-based subsidiary of US health care giant Johnson & Johnson is disappointed with the Scottish…

JanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationUKZytiga

Institute of Cancer Research study of Zytiga contradicts NICE's rejection for advanced prostate cancer

Institute of Cancer Research study of Zytiga contradicts NICE's rejection for advanced prostate cancer

05-02-2015

A study by the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust has…

Johnson & JohnsonOncologyPharmaceuticalResearchZytiga

FDA expands approval of Johnson & Johnson/Pharmacyclics' Imbruvica to Waldenstrom’s macroglobulinemia

FDA expands approval of Johnson & Johnson/Pharmacyclics' Imbruvica to Waldenstrom’s macroglobulinemia

30-01-2015

The US Food and Drug Administration has expanded approval of Johnson & Johnson and Pharmacyclics’ Imbruvica…

HematologyImbruvicaJohnson & JohnsonPharmaceuticalPharmacyclicsRegulationUSA

Applied Molecular Transport inks research and license agreement with Janssen on IBD therapy

Applied Molecular Transport inks research and license agreement with Janssen on IBD therapy

28-01-2015

Biopharma company Applied Molecular Transport has entered into a research collaboration and license agreement…

Applied Molecular TransportGastro-intestinalsJanssenJohnson & JohnsonLicensingPharmaceutical

Depomed pays over $1 billion for US rights to Janssen’s Nucynta franchise

Depomed pays over $1 billion for US rights to Janssen’s Nucynta franchise

16-01-2015

US specialty drugmaker Depomed has entered into a definitive agreement to acquire the US rights to the…

DepomedGrunenthalJanssenJohnson & JohnsonLicensingNeurologicalNucyntaPharmaceuticalUSA

Valneva to acquire Dukoral vaccine from Crucell

07-01-2015

France-based biotech firm Valneva has entered into an agreement with Crucell Holland (part of Johnson…

CrucellDukoralJohnson & JohnsonMergers & AcquisitionsPharmaceuticalVaccinesValneva

Top 30 Pharmas spent $112 billion on R&D in 2013; report

Top 30 Pharmas spent $112 billion on R&D in 2013; report

17-12-2014

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development…

FinancialGlobalGlobalDataJohnson & JohnsonNovartisPfizerPharmaceuticalPharmaceutical sciencesResearch

Genesis One Nucleus 2014: personalized medicine and big data

Genesis One Nucleus 2014: personalized medicine and big data

10-12-2014

In the opening sessions at the Genesis One Nucleus 2014 conference in London yesterday, the main themes…

Evidence-based medicineHealth Medical PharmaInterviewsJohnson & JohnsonPharmaceuticalResearch

1 to 9 of 415 results

COMPANY SPOTLIGHT

Menarini

Back to top